While drugs like imatinib, sunitinib, and other tyrosine kinase inhibitors with inhibitory activity against KIT have shown anecdotal responses in a few patients, phase II trials of imatinib in non-selected thymic carcinomas have yielded disappointing results [33,34]. This evidence concerns the gene KIT and thymic carcinoma.